CFA
ATRA icon

CT Financial Advisors’s Atara Biotherapeutics ATRA Stock Holding History

CT Financial Advisors’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-16
Closed -$10.7K – 632
2014
Q4 		$10.7K Buy
+16
New +$9.77K 0.01% 380

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BM
Bridger Management New York $150M AUM 17.71% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CT Financial Advisors's ATRA Position: Q1 2015 in Review

CT Financial Advisors sold out of Atara Biotherapeutics (ATRA) in Q1 2015, closing a stake of 16 shares — an estimated $10.7K sold.

CT Financial Advisors first reported a position in ATRA in Q4 2014 and held it in 1 quarter. The position peaked at $10.7K in Q4 2014. 53 funds tracked by Wall St. Rank hold ATRA as of Q1 2015.

  • CT Financial Advisors reported no remaining Atara Biotherapeutics position as of Q1 2015 after selling out during the quarter.
  • CT Financial Advisors sold 16 Atara Biotherapeutics shares in Q1 2015, an estimated $10.7K.
  • CT Financial Advisors first reported a position in Atara Biotherapeutics in Q4 2014 and held it in 1 quarter.
  • CT Financial Advisors's Atara Biotherapeutics position peaked at $10.7K in Q4 2014.
  • 53 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2015.

Based on CT Financial Advisors's 13F filing for Q1 2015, filed 7 May 2015.